Maiwei Biotechnology-B (02493): 9MW2821 reported the latest clinical data in oral and poster form at the 2026 European Society for Medical Oncology Gynecologic Oncology Annual Meeting (ESMO Gynae).

The Intelligenz Financial APP reported that Maiwei Biotech-B (02493) has announced that the company will present the latest results of the Phase I/II clinical study of the targeted Nectin-4 ADC innovative drug 9MW2821 (Bulumtatug Fuvedotin, BFv) for the treatment of recurrent or metastatic cervical cancer patients at the 2026 European Society for Medical Oncology Gynaecological Cancers Congress in Copenhagen, Denmark from June 17 to June 19, 2026, in the form of an oral presentation.